Foamix Pharmaceuticals Ltd (FOMX) Can’t Be More Safe. Trades Significantly Higher

September 17, 2017 - By Marguerite Chambers

The stock of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) is a huge mover today! The stock increased 4.20% or $0.21 on September 15, reaching $5.21. About 127,069 shares traded or 67.18% up from the average. Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has declined 30.16% since September 17, 2016 and is downtrending. It has underperformed by 46.86% the S&P500.
The move comes after 7 months positive chart setup for the $194.99 million company. It was reported on Sep, 17 by Barchart.com. We have $5.42 PT which if reached, will make NASDAQ:FOMX worth $7.80M more.

Investors wait Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) to report on November, 21. its quarterly earnings Wall Street analysts expect $-0.44 earnings per share, down $0.25 or 131.58 % from last year’s $-0.19 same quarter earnings. Foamix Pharmaceuticals Ltd’s Wall Street analysts see 0.00 % EPS growth, taking into account the $-0.44 EPS reproted in the previous quarter,

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Ratings Coverage

Among 2 analysts covering Foamix Pharmaceuticals (NASDAQ:FOMX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Foamix Pharmaceuticals had 3 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) earned “Hold” rating by Zacks on Tuesday, August 25.

More notable recent Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) news were published by: Seekingalpha.com which released: “Foamix Pharmaceuticals’ (FOMX) CEO Dov Tamarkin on Q4 2016 Results – Earnings …” on February 22, 2017, also Prnewswire.com with their article: “Foamix Reports First Quarter 2017 Financial Results and Provides Business Update” published on May 09, 2017, Seekingalpha.com published: “Foamix Pharmaceuticals’ (FOMX) CEO Dave Domzalski on Q2 2017 Results …” on August 09, 2017. More interesting news about Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) were released by: Seekingalpha.com and their article: “High-Potential Pipeline And Sufficient Cash Make Foamix Pharmaceuticals A …” published on March 23, 2017 as well as Globenewswire.com‘s news article titled: “Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update” with publication date: August 08, 2017.

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The company has market cap of $194.99 million. The Firm is engaged in the development and commercialization of foam formulations, using its technology, which includes its foam platforms. It currently has negative earnings. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.